Shannon A Carty, MD
Assistant Professor of Internal Medicine
Associate Director Academic Program
Immunology Graduate Program
[email protected]

Available to mentor
Shannon A Carty, MD
Assistant Professor
  • Qualifications
  • Center Memberships
  • Recent Publications
    • Qualifications
    • MD
      Albert Einstein College of Medicine, 1300 Morris Park Avenue, 2006
    • AB
      Harvard University, magna cum laude, Cambridge, 2000
    Center Memberships
    • Center Member
      Rogel Cancer Center
    Recent Publications See All Publications
    • Proceeding / Abstract / Poster
      Endoplasmic reticulum associated degradation adaptor Sel1L regulates T cell survival and homeostasis
      Dils AT, Correa LO, Gronevelt JP, Liu L, Kadiyala P, Li Q, Carty SA. The Journal of Immunology, 2021 May 1; 206 (1_Supplement): 98.44 - 98.44. DOI:10.4049/jimmunol.206.supp.98.44
    • Journal Article
      TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function.
      Dimitri AJ, Baxter AE, Chen GM, Hopkins CR, Rouin GT, Huang H, Kong W, Holliday CH, Wiebking V, Bartoszek R, Drury S, Dalton K, Koucky OM, Chen Z, Giles JR, Dils AT, Jung I-Y, O'Connor R, Collins S, Everett JK, Amses K, Sherrill-Mix S, Chandra A, Goldman N, Vahedi G, Jadlowsky JK, Young RM, Melenhorst JJ, Maude SL, Levine BL, Frey NV, Berger SL, Grupp SA, Porter DL, Herbst F, Porteus MH, Carty SA, Bushman FD, Weber EW, Wherry EJ, Jordan MS, Fraietta JA. Sci Adv, 2024 Nov 15; 10 (46): eadp9371 DOI:10.1126/sciadv.adp9371
      PMID: 39536093
    • Presentation
      Lymphoma Roundtable
      Carty S, Kaminski M, Karimi Y, Weiss J, Wilcox R. 2024 Oct 19;
    • Journal Article
      S4545 Simultaneous Presentation of Post-Transplant Lymphoproliferative Disorder (PTLD) and Acute Cellular Rejection (ACR) in a Liver Transplant Recipient: A Therapeutic Conundrum
      Mishra A, Kathuria P, Peddu D, Kubina M, Kwon H, Carty S, Bloom P. The American Journal of Gastroenterology, 2024 Oct; 119 (10S): s2893 - s2894. DOI:10.14309/01.ajg.0001047548.68165.3f
    • Proceeding / Abstract / Poster
      ABCL-616 Incidence, Characteristics and Outcomes in Relapsed and Refractory CD20+ PTLD: An Institutional Retrospective Cohort Study
      El-amir Z, McLane M, Kaminski M, Phillips T, Wilcox R, Sano D, Karimi Y, Carty S. Clinical Lymphoma Myeloma & Leukemia, 2024 Sep; 24: s486 DOI:10.1016/s2152-2650(24)01542-8
    • Proceeding / Abstract / Poster
      Incidence, Characteristics and Outcomes in Relapsed and Refractory CD20+ PTLD: An Institutional Retrospective Cohort Study
      El-amir Z, McLane M, Kaminski M, Phillips T, Wilcox R, Sano D, Karimi Y, Carty S. Clinical Lymphoma Myeloma and Leukemia, 2024 Sep; 24: S219 - S219. DOI:10.1016/s2152-2650(24)00836-x
    • Proceeding / Abstract / Poster
      Incidence, characteristics and outcomes in relapsed and refractory CD20+ PTLD: An institutional retrospective cohort study.
      El-amir Z, McLane MJ, Kaminski MS, Phillips TJ, Wilcox RA, Sano D, Karimi Y, Carty S. Journal of Clinical Oncology, 2024 Jun 1; 42 (16_suppl): e19078 - e19078. DOI:10.1200/jco.2024.42.16_suppl.e19078
    • Proceeding / Abstract / Poster
      Outcomes and prognostic factors of patients diagnosed with relapsed/refractory primary B-cell lymphoma: A retrospective study.
      Dumke H, Phillips TJ, Kaminski MS, Carty S, Wilcox RA, Sano D, Kandarpa M, Polk A, Karimi Y. Journal of Clinical Oncology, 2024 Jun 1; 42 (16_suppl): 7081 - 7081. DOI:10.1200/jco.2024.42.16_suppl.7081